After identifying
a potential drug which meets basic criteria, VDDI Pharmaceuticals will conduct
extensive due diligence on the compound at its own expense (see
below). VDDI Pharmaceuticals expects that approximately 80% of drugs which satisfy
the basic criteria will be subsequently rejected at some stage
of due diligence review.
To reduce the risk to investors, VDDI Pharmaceuticals aims to develop a diverse
portfolio of selected product targets, which will result in the
reduction in risk associated with a one product, one technology
approach. VDDI Pharmaceuticals will "package" approximately four different
technologies, which have successfully passed the due diligence
review, into development programs (e.g., wholly own subsidiaries)
which will be managed by VDDI Pharmaceuticals. VDDI Pharmaceuticals will then seek private equity
financing, entertain aggressive royalty streams, and seek partnerships
with Pharma and or Biotechnology companies for success based income
(milestone payments). Each development program will have a dedicated
drug development team and will be operated in accordance with
a strict budget and timeline.
